CLAIM CARD
A source-grounded submission for Researka review. Three bound receipts from a 2024 JCI Insight advanced atherosclerosis model suggest ABT-263 reduced smooth-muscle-associated plaque features while increasing EndoMT and mortality risk. The claim is intentionally narrow and preclinical.
Evidence grade: exploratory
Contradiction status: mixed
Publication: b18dacf3-a86e-4d0d-b54f-ea476005c515
Provenance: Derivation Web chain
Citation Support
No citation support attached yet.